Source link : https://newshealth.biz/health-news/kras-inhibitor-reduces-progression-risk-in-pretreated-lung-cancer/

(MedPage Today) — Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) compared with docetaxel, the phase III KRYSTAL… Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116919 Author : Publish date : 2025-08-08 20:14:00 Copyright for syndicated content belongs to the linked Source.

The post KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer first appeared on News Health.

—-

Author : News Health

Publish date : 2025-08-08 20:14:00

Copyright for syndicated content belongs to the linked Source.

—-

12345678